Business
Interim Results
Interim Results.
About this update from Inspiration Healthcare Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 9820N\n Inspiration Healthcare Group PLC\n 05 October 2021\n \n \n \n \n \"This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"MAR\") and is disclosed in accordance with the Company's obligations under Article 17 of MAR. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.\"\n \n \n Inspiration Healthcare Group plc\n (\"Inspiration Healthcare\", the \"Company\" or the \"Group\")\n 5 October 2021\n \n Interim Results\n \n Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, today announces its unaudited interim results for the six months ended 31 July 2021 (\"H1 2021/22\"). \n \n \n Financial highlights\n \n \n · \n Total Group Revenue up by 47% to £20.9m \n \n \n · \n Gross Margin up from 51.4% to 52.5% \n \n \n · \n Branded products represent 55% of total Group Revenue\n \n \n · \n EBITDA1 up 42% to £3.6m \n \n \n · \n Operating Profit up 140% to £2.6m \n \n \n · \n Net cash position of £8.6m \n \n \n \n 1\n \n Earnings before interest, tax, depreciation, share based payments and non-trading items\n \n \n Operational highlights\n \n \n · \n Successful integration of SLE Ltd continues in line with operational plans\n \n \n · \n Synergies and cross selling opportunities being realised \n \n \n · \n New regulatory approvals secured for key products (SLE6000) in China and Japan\n \n \n · \n AlphaCore, patient warming portfolio has seen increased demand within UK market with units placed up by 104% compared to the equivalent period of last financial year\n \n \n · \n Increased investment in R&D to fast-track product development\n \n \n · \n The Queens Award for Enterprise for Innovation was awarded to SLE Ltd for the Oxygenie® product\n \n \n · \n Project WAVE recruited first patient in University Hospitals Sussex (formerly Brighton and Sussex University NHS Trust)\n \n \n · \n Micrel SA - UK and Ireland distribution agreement renewed\n \n \n \n \n \n Neil Campbell, Chief Executive Officer, said today:\n \n \n \"Our revenues are in line with management expectations with c...